L. Holden

EMA/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients.

Mark Bower, E.S. Newlands, L. Holden et al. · Journal of Clinical Oncology · 1997 · 311 citations

Medicine, Gynecology, Oncology +17

Low-Risk Persistent Gestational Trophoblastic Disease: Outcome After Initial Treatment With Low-Dose Methotrexate and Folinic Acid From 1992 to 2000

Iain A. McNeish, Sarah Strickland, L. Holden et al. · Journal of Clinical Oncology · 2002 · 248 citations

Medicine, Pharmacology, Pharmacotherapy +11

Etoposide and Cisplatin/Etoposide, Methotrexate, and Actinomycin D (EMA) Chemotherapy for Patients With High-Risk Gestational Trophoblastic Tumors Refractory to EMA/Cyclophosphamide and Vincristine Chemotherapy and Patients Presenting With Metastatic Placental Site Trophoblastic Tumors

E.S. Newlands, Paul Mulholland, L. Holden et al. · Journal of Clinical Oncology · 2000 · 223 citations

Medicine, Oncology, Pharmacology +15

Combination but not single-agent methotrexate chemotherapy for gestational trophoblastic tumors increases the incidence of second tumors.

G.J.S. Rustin, E.S. Newlands, Jean Michel Lutz et al. · Journal of Clinical Oncology · 1996 · 185 citations

Medicine, Gynecology, Oncology +17

Results with the EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) regimen in high risk gestational trophoblastic tumours, 1979 to 1989

E.S. Newlands, K. D. Bagshawe, Richard H. J. Beǵent et al. · BJOG An International Journal of Obstetrics & Gynaecology · 1991 · 183 citations

Medicine, Gynecology, Oncology +11